Catabasis Uses New Financing To Take Two Programs Forward Simultaneously
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech now has the funding to move a second program into the clinic; a program it hopes to carry to approval on its own.
You may also be interested in...
Amarin Seeks AMR101 Approval; Hopes To Begin Commercialization Of First Product
The New Jersey biotech submitted the NDA for its omega-3 fatty acid drug with FDA.
As It Soaks Up Good Trial Results, Amarin Ponders Partners - Or None
A second set of clinical trial results expands the potential market for AMR101 tenfold, triggering increased investor and partnership interest.
Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?
Nutritional industry stakeholders say the jury is still out on how omega-3 pharmaceuticals will affect the supplement space long-term, but supplement marketers should do everything they can to step up their game.